Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels
TNDM(NASDAQ:TNDM) SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insul
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDM
TNDM(NASDAQ:TNDM) NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public. So What: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees or costs throu
Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones
TNDM(NASDAQ:TNDM) SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem t:slim Mobile App authorized by Health Canada for iPhone and Android Phones. The app will be available for Canadian customers later this year.
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
TNDMLOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happ
Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
TNDMBENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TANDEM DIABETES CARE, INC. (TNDM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your lega
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
TNDMLOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 7, 2025, Tandem disclosed that a malfuncti
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps
TNDMSAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery. The error, which appears as a Malfunction 16 alarm to the user, will stop insulin delivery and terminate communication between the insulin pump and the continuous glucose monitoring (CGM) device. If not addressed, this
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance
TNDMSAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and sequential gross margin improvement. Initiated an early access program for the t:slim X2™ insulin pump w
Tandem Diabetes Agrees To Develop And Commercialize Integrated Diabetes Solutions Combining Abbott's Future Dual Glucose-Ketone Sensor With Tandem's Insulin Delivery Systems To Provide More Options For People To Manage Diabetes
TNDMTandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
TNDMSAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to h
Tandem Diabetes Care Enters Settlement Agreement With Roche Entities; Settlement Resolves Disputes Related To T:Slim X2 Pump Patents; To Pay Roche $36M Over Five Years
TNDMWhere Tandem Diabetes Care Stands With Analysts
TNDMCitigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $24
TNDMCanaccord Genuity Maintains Buy on Tandem Diabetes Care, Raises Price Target to $59
TNDMStifel Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $31
TNDMWells Fargo Maintains Equal-Weight on Tandem Diabetes Care, Lowers Price Target to $20
TNDMPiper Sandler Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $30
TNDMTandem Diabetes Care Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
TNDMBaird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $24
TNDMTandem Diabetes Care Affirms FY2025 Sales Guidance of $997.00M-$1.01B vs $999.58M Est
TNDMTandem Diabetes Care Q1 Adj. EPS $(0.67) Misses $(0.61) Estimate, Sales $234.42M Beat $220.20M Estimate
TNDMTandem Diabetes Care Q1 GAAP EPS $(1.97), Sales $234.42M Beat $220.20M Estimate
TNDMInsights into Tandem Diabetes Care's Upcoming Earnings
TNDMForecasting The Future: 9 Analyst Projections For Tandem Diabetes Care
TNDMMizuho Initiates Coverage On Tandem Diabetes Care with Neutral Rating, Announces Price Target of $20
TNDMTandem Diabetes Announces NEJM Publication Of Control-IQ+ Trial For Type 2 Diabetes, Showing Significant A1C Reductions Of 0.9% Overall And 2.3% For A1C ≥9%, Meeting Primary Endpoint
TNDMMorgan Stanley Downgrades Tandem Diabetes Care to Equal-Weight, Lowers Price Target to $22
TNDMCitigroup Downgrades Tandem Diabetes Care to Neutral, Lowers Price Target to $24
TNDMGoldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $24
TNDMWells Fargo Downgrades Tandem Diabetes Care to Equal-Weight, Lowers Price Target to $22
TNDMRBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $55
TNDMThe Analyst Verdict: Tandem Diabetes Care In The Eyes Of 4 Experts
TNDMTandem Diabetes Care Sees Q1 Revenue $219M-$224M Vs 221.593M Est.
TNDMTandem Diabetes Care Sees FY25 Revenue $997M-$1.007B Vs $1.008B Est.
TNDMTandem Diabetes Care Q4 2024 GAAP EPS $0.01 Beats $(0.21) Estimate, Sales $282.648M Beat $251.982M Estimate
TNDMCanaccord Genuity Maintains Buy on Tandem Diabetes Care, Maintains $63 Price Target
TNDMTandem Diabetes Care Announces FDA Clearance For Control-IQ+ Technology For Type 2 Diabetes, Available March 2025
TNDMTandem Diabetes Sees FY24 Sales $903M-$910M Vs $890.982M Est
TNDMTandem Diabetes Care Q3 2024 GAAP EPS $(0.35) Beats $(0.42) Estimate, Sales $244.000M Beat $223.663M Estimate
TNDMThe Analyst Verdict: Tandem Diabetes Care In The Eyes Of 5 Experts
TNDMBernstein Initiates Coverage On Tandem Diabetes Care with Outperform Rating, Announces Price Target of $42
TNDMLake Street Maintains Buy on Tandem Diabetes Care, Raises Price Target to $75
TNDMCitigroup Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $57
TNDMExpert Ratings For Tandem Diabetes Care
TNDMStifel Maintains Buy on Tandem Diabetes Care, Raises Price Target to $55
TNDMRecap: Tandem Diabetes Care Q1 Earnings
TNDMTandem Diabetes Care (NASDAQ:TNDM) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Tandem Raises FY22 Sales Guidance From $845M-$860M To $850M-$865M vs $846.54M Est.
TNDMTandem Diabetes Care Q1 EPS $(0.23) Misses $(0.07) Estimate, Sales $175.90M Beat $168.43M Estimate
TNDM